176 related articles for article (PubMed ID: 21261003)
1. [Inhibitors of the heat shock protein 90 activity: a novel class of tumor radiosensitizers].
Kabakov AE; Kudriavtsev VA; Makarova IuM
Radiats Biol Radioecol; 2010; 50(5):528-35. PubMed ID: 21261003
[TBL] [Abstract][Full Text] [Related]
2. Hsp90 inhibitors as promising agents for radiotherapy.
Kabakov AE; Kudryavtsev VA; Gabai VL
J Mol Med (Berl); 2010 Mar; 88(3):241-7. PubMed ID: 19946660
[TBL] [Abstract][Full Text] [Related]
3. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
Hashida S; Yamamoto H; Shien K; Ohtsuka T; Suzawa K; Maki Y; Furukawa M; Soh J; Asano H; Tsukuda K; Miyoshi S; Kanazawa S; Toyooka S
Oncol Rep; 2015 Mar; 33(3):1499-504. PubMed ID: 25607753
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Hsp90: a multitarget approach to radiosensitization.
Camphausen K; Tofilon PJ
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4326-30. PubMed ID: 17671112
[TBL] [Abstract][Full Text] [Related]
5. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
Workman P; Burrows F; Neckers L; Rosen N
Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
[TBL] [Abstract][Full Text] [Related]
6. Induction of Heat Shock Protein 70 as a Predictive Marker of the Tumor Cell Radiosensitization with Inhibitors of the Heat Shock Protein 90 Activity.
Kudryavtsev VA; Khokhlova V AV; Mosina A; Makarova YM; Kabakov AE
Radiats Biol Radioecol; 2016 Sep; 56(5):494-502. PubMed ID: 30703309
[TBL] [Abstract][Full Text] [Related]
7. Induction of Hsp70 in tumor cells treated with inhibitors of the Hsp90 activity: A predictive marker and promising target for radiosensitization.
Kudryavtsev VA; Khokhlova AV; Mosina VA; Selivanova EI; Kabakov AE
PLoS One; 2017; 12(3):e0173640. PubMed ID: 28291803
[TBL] [Abstract][Full Text] [Related]
8. A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer.
Kinzel L; Ernst A; Orth M; Albrecht V; Hennel R; Brix N; Frey B; Gaipl US; Zuchtriegel G; Reichel CA; Blutke A; Schilling D; Multhoff G; Li M; Niyazi M; Friedl AA; Winssinger N; Belka C; Lauber K
Oncotarget; 2016 Jul; 7(28):43199-43219. PubMed ID: 27259245
[TBL] [Abstract][Full Text] [Related]
9. Sensitizing tumor cells to radiation by targeting the heat shock response.
Schilling D; Kühnel A; Konrad S; Tetzlaff F; Bayer C; Yaglom J; Multhoff G
Cancer Lett; 2015 May; 360(2):294-301. PubMed ID: 25721082
[TBL] [Abstract][Full Text] [Related]
10. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
Moser C; Lang SA; Stoeltzing O
Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
[TBL] [Abstract][Full Text] [Related]
11. [Hsp90--a target for anticancer therapy].
Růcková E; Müller P; Vojtesek B
Klin Onkol; 2011; 24(5):329-37. PubMed ID: 22070013
[TBL] [Abstract][Full Text] [Related]
12. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
13. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
Yin X; Zhang H; Lundgren K; Wilson L; Burrows F; Shores CG
Int J Cancer; 2010 Mar; 126(5):1216-25. PubMed ID: 19662650
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HSP90 molecular chaperones: moving into the clinic.
Garcia-Carbonero R; Carnero A; Paz-Ares L
Lancet Oncol; 2013 Aug; 14(9):e358-69. PubMed ID: 23896275
[TBL] [Abstract][Full Text] [Related]
15. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
16. Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB; Whitesell L
Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
[TBL] [Abstract][Full Text] [Related]
17. The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer.
Ischia J; Saad F; Gleave M
Curr Opin Urol; 2013 May; 23(3):194-200. PubMed ID: 23385973
[TBL] [Abstract][Full Text] [Related]
18. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
Messaoudi S; Peyrat JF; Brion JD; Alami M
Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
[TBL] [Abstract][Full Text] [Related]
19. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
[TBL] [Abstract][Full Text] [Related]
20. HSP90 and its inhibitors.
Hao H; Naomoto Y; Bao X; Watanabe N; Sakurama K; Noma K; Motoki T; Tomono Y; Fukazawa T; Shirakawa Y; Yamatsuji T; Matsuoka J; Takaoka M
Oncol Rep; 2010 Jun; 23(6):1483-92. PubMed ID: 20428801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
